Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.

Type
Public
HQ
Salt Lake City, US
Founded
1997
Size (employees)
14 (est)
Lipocine was founded in 1997 and is headquartered in Salt Lake City, US
Report incorrect company information

Key People/Management at Lipocine

Mahesh Patel

Mahesh Patel

Chairman, President and Chief Executive Officer
Morgan Brown

Morgan Brown

Executive Vice President and Chief Financial Officer
Greg Bass

Greg Bass

Executive Vice President and Chief Commercial Officer
Jyrki Mattila

Jyrki Mattila

Executive Vice President and Chief Business Officer
Anthony DelConte M.D

Anthony DelConte M.D

Chief Medical Director

Lipocine Office Locations

Lipocine has offices in Lawrence and Salt Lake City
Salt Lake City, US (HQ)
202 675 Arapeen Dr
Lawrence, US
3150 Brunswick Pike, Suite 130
Show all (2)
Report incorrect company information

Lipocine Financials and Metrics

Lipocine Financials

USD

Revenue (Q1, 2018)

428 k

Net income (Q1, 2018)

(2.7 m)

EBIT (Q1, 2018)

(2.6 m)

Market capitalization (22-Jun-2018)

27 m

Closing share price (22-Jun-2018)

1.3

Cash (31-Mar-2018)

8.6 m
Lipocine's current market capitalization is $27 m.
Annual
USDY, 2013FY, 2016FY, 2017

General and administrative expense

10.4 m10.2 m

R&D expense

8.1 m11 m

Operating expense total

18.5 m21.2 m

EBIT

(10.7 m)(19.2 m)(21.2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

428 k

General and administrative expense

1.2 m1.9 m1 m871.8 k1.1 m1.1 m1.7 m4.4 m3.2 m1.4 m1.8 m2 m1.7 m

R&D expense

1.6 m3.4 m6 m3.2 m1.9 m3.2 m4.7 m2.7 m2.6 m1.5 m3.1 m4.1 m1.4 m

Operating expense total

2.8 m5.3 m7 m4.1 m3 m4.3 m6.4 m7.1 m5.8 m3.3 m4.9 m6.1 m4.8 m3.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

45.3 m27.7 m20 m5.6 m3.2 m

Accounts Receivable

Inventories

Current Assets

46 m27.9 m44.9 m27.2 m25.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

36.8 m41.8 m34.2 m31.7 m24.8 m38.3 m23.9 m14.1 m12.4 m4.7 m6.9 m16.6 m9.3 m8.6 m

Current Assets

37.1 m42 m35.4 m32 m25 m44.1 m42.3 m38.6 m33.2 m29.4 m27.1 m27.9 m26.1 m31.6 m

Total Assets

37.2 m42.1 m35.5 m32 m25.1 m53.8 m48.4 m38.8 m33.3 m29.6 m27.2 m28 m26.3 m31.7 m

Accounts Payable

1.5 m773 k641.8 k399.1 k379.5 k398.8 k456.8 k1.1 m989 k865 k853.5 k1.1 m803.8 k388.4 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(10.6 m)(20.4 m)(18.2 m)(19 m)(21 m)

Depreciation and Amortization

21.8 k14.6 k26.7 k32 k28.4 k

Inventories

Accounts Payable

668.8 k(449.6 k)200.8 k(261.2 k)352.2 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Net Income

(3.5 m)(5.3 m)(7 m)(4.1 m)(3 m)(4.2 m)(6.4 m)(7 m)(5.8 m)(3.2 m)(4.9 m)(4.7 m)(2.7 m)

Depreciation and Amortization

5.3 k

Accounts Payable

641.8 k399.1 k379.5 k398.8 k456.8 k1.1 m989 k865 k853.5 k803.8 k(209.7 k)

Cash From Financing Activities

10 m
USDY, 2018

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information